TrialComparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis
Trial details
- Registry ID
- NCT02644941
- Phase
- Phase 3
HUMA
Humacyte, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
6Trials in this database
11Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for HemodialysisNCT02644941 | HUMA | Phase 3 | Completed | 2019-05Actual |
| Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PADNCT02887859 | HUMA | Phase 2 | Completed | 2020-12Actual |
| Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular TraumaNCT03005418 | HUMA | Phase 2, Phase 3 | Completed | 2023-09-19Actual |
| Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for HemodialysisNCT03183245 | HUMA | Phase 3 | Completed | 2024-04-22Actual |
| Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for DialysisNCT04135417 | HUMA | Phase 2 | Completed | 2021-05-15Actual |
| To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring HemodialysisNCT05908084 | HUMA | Phase 3 | Active not recruiting | 2027-06Estimated |
Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD
Trial details
- Registry ID
- NCT02887859
- Phase
- Phase 2
Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma
Trial details
- Registry ID
- NCT03005418
- Phase
- Phase 2, Phase 3
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
Trial details
- Registry ID
- NCT03183245
- Phase
- Phase 3
Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for Dialysis
Trial details
- Registry ID
- NCT04135417
- Phase
- Phase 2
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
Trial details
- Registry ID
- NCT05908084
- Phase
- Phase 3
Latest recorded trial changes
Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma
NCT03005418 · Humacyte, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: ATEV Primary Patency - Extremity Group (Non-iatrogenic)
Measure: Rate of ATEV Infection - Extremity Group (Non-iatrogenic)
Measure: Number of Participants With Adverse Events for Each Severity Grade - Extremity Group (Non-iatrogenic)
+ After
Measure: Primary Patency Rate of the Human Acellular Vessel (HAV) at Day 30 in the All HAV Group Measure: Primary Patency Rate of the Human Acellular Vessel (HAV) at Day 30 in the Extremity Community-Acquired Trauma Subgroup
Actual enrollment increased by 21 participants
− Before
51 participants (actual)
+ After
72 participants (actual)
Primary completion date changed
− Before
30 Jun 2023
+ After
19 Sep 2023
Recruitment status changed
− Before
Active not recruiting
+ After
Completed
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
NCT05908084 · Humacyte, Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
150 participants (planned)
+ After
121 participants (actual)
Primary completion date changed
− Before
Oct 2026
+ After
Jun 2027
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
NCT03183245 · Humacyte, Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
240 participants (planned)
+ After
242 participants (actual)
Recruitment status changed
− Before
Active not recruiting
+ After
Completed